Mustang Bio, Inc.

NasdaqCM:MBIO Stock Report

Market Cap: US$9.5m

Mustang Bio Management

Management criteria checks 4/4

Mustang Bio's CEO is Manny Litchman, appointed in Apr 2017, has a tenure of 7.58 years. total yearly compensation is $501.84K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $15.28K. The average tenure of the management team and the board of directors is 2.7 years and 7.6 years respectively.

Key information

Manny Litchman

Chief executive officer

US$501.8k

Total compensation

CEO salary percentage95.8%
CEO tenure7.6yrs
CEO ownership0.2%
Management average tenure2.7yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Mustang Bio: This Horse May Gallop Still

Sep 23

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Aug 09
Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio: The Market Is Missing This Opportunity

May 03

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Dec 29
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

Sep 14

Mustang Bio (MBIO) EHA Investor Presentations - Slideshow

Jun 18

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23
What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28
Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

CEO Compensation Analysis

How has Manny Litchman's remuneration changed compared to Mustang Bio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$32m

Mar 31 2024n/an/a

-US$40m

Dec 31 2023US$502kUS$481k

-US$52m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$72m

Mar 31 2023n/an/a

-US$74m

Dec 31 2022US$636kUS$448k

-US$78m

Sep 30 2022n/an/a

-US$78m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$885kUS$450k

-US$66m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$1mUS$430k

-US$60m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$53m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$517kUS$415k

-US$46m

Sep 30 2019n/an/a

-US$42m

Jun 30 2019n/an/a

-US$39m

Mar 31 2019n/an/a

-US$34m

Dec 31 2018US$606kUS$403k

-US$31m

Sep 30 2018n/an/a

-US$34m

Jun 30 2018n/an/a

-US$34m

Mar 31 2018n/an/a

-US$34m

Dec 31 2017US$6mUS$267k

-US$31m

Compensation vs Market: Manny's total compensation ($USD501.84K) is about average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Manny's compensation has been consistent with company performance over the past year.

CEO

Manny Litchman (70 yo)

7.6yrs

Tenure

US$501,838

Compensation

Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio, Inc. since April 24, 2017 also serves as an Interim CFO since November 15, 2024 a...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Weiss
Executive Chairman9.5yrsUS$110.00k0.034%
$ 3.3k
Manuel Litchman
President7.6yrsUS$501.84k0.16%
$ 15.3k
Peter Carney
Controller & Interim Chief Accounting Officerless than a yearno data0.0053%
$ 502.0
Matthew Wein
VP & General Counsel3.2yrsno datano data
Debra Manning
Senior VP & Head of Human Resources5.8yrsno datano data
Lynn Bayless
VP & Head of Regulatory Affairs4.7yrsno datano data
Bruce Dezube
Senior VP & Head of Clinical Development3.4yrsno datano data
Greg Furrow
Chief Quality Officer1.8yrsno datano data
Richard Bodmer
Head of CMC Development2.3yrsno datano data
Robert Sexton
VP and Head of Program & Alliance Leadership1.8yrsno datano data
Kerry Biron
VP & Head of Clinical Operations1.8yrsno datano data
James Edinger
Senior VP & Head of Preclinical Sciences1.8yrsno datano data

2.7yrs

Average Tenure

58yo

Average Age

Experienced Management: MBIO's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Weiss
Executive Chairman9.5yrsUS$110.00k0.034%
$ 3.3k
Manuel Litchman
President7.6yrsUS$501.84k0.16%
$ 15.3k
Lindsay Rosenwald
Non-Executive Director9.7yrsUS$100.00k0.057%
$ 5.4k
Michael Zelefsky
Independent Director7.4yrsUS$100.00k0.040%
$ 3.8k
Neil Herskowitz
Independent & Non-Executive Director9.3yrsUS$100.00k0.041%
$ 3.9k
Adam Chill
Independent Director7.4yrsUS$110.00k0.040%
$ 3.8k
David Jin
Directorless than a yearno data0.0042%
$ 398.9

7.6yrs

Average Tenure

64yo

Average Age

Experienced Board: MBIO's board of directors are considered experienced (7.6 years average tenure).